Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10278958-B2
Publication Date
2019-05-07
Expiration Date
Abstract
Provided is a method for reducing a potential for neurological damage of an animal at risk of head injury, by administering to the animal before exposure to the risk indole-3-propionic acid, indole lactic acid, or a salt, ester or protein complex or marginally bound preparation thereof, or a mixture thereof, in a suitable carrier.
Core Innovation
The document describes indole-3-propionic acid (IPA, also referred to as I3PA) and indole lactic acid as a protective agent and as a disease biomarker. Using LC-EC and parallel LC-EC/LC-MS approaches, significantly lower IPA levels are identified in multiple disease states, including Huntington’s disease, Alzheimer’s disease/MCI, ALS/LMND, Parkinson’s disease, and ischemic heart disease/stroke/mental stress. It also states that IPA levels are individually stable and are largely genetically and microbiome determined, and that IPA can cross the BBB.
The document further describes mechanistic support in which oxidative or free-radical processing of I3PA can generate protein-bound oxidation products including kynuric acid derivatives. It presents supporting evidence for oxidative processing involving protein targets, including HSA, ubiquitin, and angiotensin I, and discusses a related Fenton binding study context. The overall framing connects IPA to protection through antioxidant and protein-aggregation suppression.
In addition, the document describes gut microbiome contribution evidence showing microbiome “footprint” differences that are predictive or classifying for disease and genotype, using mouse models including CAG140, R6/2, and G93A. It also outlines non-invasive or home sampling approaches using urine and feces dried on filter paper/toilet-paper matrices, and targeted analytical methods for biomarker tracking. It further states a brewer’s yeast protein-bound IPA preparation is provided to deliver IPA to the gut, and positions IPA biomarker monitoring for therapeutic intervention and drug development.
Claims Coverage
The independent claim provides a method concept with a reducible neurological damage risk by prophylactic administration of specific indole compounds before exposure to head injury risk, with a brewer’s yeast protein binding format and a suitable carrier. The claim set includes four dependent claim refinements covering the risk scenario subject matter, administration route, a daily dosage range, and a quantitative binding proportion.
Prophylactic administration before head injury risk
Administering indole-3-propionic acid, indole lactic acid, or a salt, ester, or mixture thereof to an animal at risk of head injury before exposure to said risk, wherein the administration consists of reducing a potential for neurological damage.
Coordinately bound to a brewer's yeast protein
Providing the indole-3-propionic acid, indole lactic acid, or a salt, ester, or mixture thereof in a form coordinately bound to a brewer's yeast protein.
Suitable carrier format
Administering the coordinately bound indole-3-propionic acid or indole lactic acid in a suitable carrier.
Defined daily dose rate
Administering indole-3-propionic acid or indole lactic acid (or a salt, ester, or mixture thereof) at a daily dose rate of 1 to 1500 mg per day.
Oral administration
Administering indole-3-propionic acid or indole lactic acid (or a salt, ester, or mixture thereof) orally.
Quantitative binding proportion
Providing the indole-3-propionic acid or indole lactic acid (or a salt, ester, or mixture thereof) such that 70-85% is coordinately bound to said brewer's yeast protein.
Contact sport or battle risk in humans
Specifying that the risk involves a contact sport or battle and that the animal is a human.
Across the claim set, the inventive coverage centers on prophylactically administering indole-3-propionic acid or indole lactic acid before head injury exposure to reduce potential neurological damage, specifically in a coordinately brewer’s yeast protein-bound form within a suitable carrier. Dependent claims further define scenario (contact sport or battle; human), route (oral), quantitative dosing (1–1500 mg/day), and quantitative binding extent (70–85% coordinately bound).
Stated Advantages
Reduce a potential for neurological damage of an animal at risk of head injury.
Provide indole-3-propionic acid or indole lactic acid in a form coordinately bound to a brewer's yeast protein.
Use IPA levels as a disease biomarker with significantly lower levels reported in multiple disease states.
Allow biomarker tracking for monitoring therapeutic intervention and drug development.
Documented Applications
Monitoring therapeutic intervention and drug development via biomarker tracking using IPA levels.
Non-invasive or home sampling using urine and feces dried on filter paper/toilet-paper matrices for targeted analytical approaches.
Protective use for animals at risk of head injury by administering indole-3-propionic acid or indole lactic acid (or salts/esters/mixtures) before exposure.
Disease association and classification uses involving microbiome “footprint” differences predictive or classifying for disease and genotype.
Interested in licensing this patent?